Jyong Biotech Ltd. MENS
Annual
Quarterly
No annual revenue total was found in Jyong Biotech Ltd.'s SEC filings.
Jyong Biotech Ltd. (MENS) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Dec 31, 2025 it held $1.2 million in cash and investments and $17.6 million in total debt.
Revenue
—
Net income
$-4.67M
Operating cash flow
$-3.04M
Free cash flow
—
EPS
$-0.06
Dividend per share
None
Shares outstanding
76.03M
Net cash
$-16.39M
FY 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MENS (Nasdaq)
- Incorporated in
- Cayman Islands
- Headquarters
- New Taipei City
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1954488
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Operating income | -$2.6M |
| Net income | -$4.7M |
| Diluted EPS | -$0.06 |
| Operating cash flow | -$3.0M |
| Total assets | $20.8M |
| Total liabilities | $45.7M |
| Stockholders' equity | -$24.9M |
| Cash and investments | $1.2M |
| Total debt | $17.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | May 15, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Feb 6, 2026 | Feb 6, 2026 |
| 6-K | Current report (foreign issuer) | Jan 9, 2026 | Jan 9, 2026 |
| 6-K | Current report (foreign issuer) | Jun 20, 2025 | Jun 18, 2025 |
All 73 Jyong Biotech Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.